400 related articles for article (PubMed ID: 26038599)
21. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling.
Mansky KC; Sankar U; Han J; Ostrowski MC
J Biol Chem; 2002 Mar; 277(13):11077-83. PubMed ID: 11792706
[TBL] [Abstract][Full Text] [Related]
22. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
23. Failure to Target RANKL Signaling Through p38-MAPK Results in Defective Osteoclastogenesis in the Microphthalmia Cloudy-Eyed Mutant.
Carey HA; Bronisz A; Cabrera J; Hildreth BE; Cuitiño M; Fu Q; Ahmad A; Toribio RE; Ostrowski MC; Sharma SM
J Cell Physiol; 2016 Mar; 231(3):630-40. PubMed ID: 26218069
[TBL] [Abstract][Full Text] [Related]
24. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
25. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
[TBL] [Abstract][Full Text] [Related]
26. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
[TBL] [Abstract][Full Text] [Related]
27. Sexual Dimorphism in MAPK-Activated Protein Kinase-2 (MK2) Regulation of RANKL-Induced Osteoclastogenesis in Osteoclast Progenitor Subpopulations.
Herbert BA; Valerio MS; Gaestel M; Kirkwood KL
PLoS One; 2015; 10(5):e0125387. PubMed ID: 25946081
[TBL] [Abstract][Full Text] [Related]
28. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
Tai TW; Su FC; Chen CY; Jou IM; Lin CF
Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-κB and MAPK pathways.
Deepak V; Kasonga A; Kruger MC; Coetzee M
Connect Tissue Res; 2015 Jun; 56(3):195-203. PubMed ID: 25405641
[TBL] [Abstract][Full Text] [Related]
30. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
[TBL] [Abstract][Full Text] [Related]
31. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function.
Li X; Udagawa N; Itoh K; Suda K; Murase Y; Nishihara T; Suda T; Takahashi N
Endocrinology; 2002 Aug; 143(8):3105-13. PubMed ID: 12130576
[TBL] [Abstract][Full Text] [Related]
32. Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway.
Yeon JT; Choi SW; Park KI; Choi MK; Kim JJ; Youn BS; Lee MS; Oh J
BMB Rep; 2012 Mar; 45(3):171-6. PubMed ID: 22449704
[TBL] [Abstract][Full Text] [Related]
33. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways.
Tiedemann K; Hussein O; Sadvakassova G; Guo Y; Siegel PM; Komarova SV
J Biol Chem; 2009 Nov; 284(48):33662-70. PubMed ID: 19801662
[TBL] [Abstract][Full Text] [Related]
35. IL-1 mediates TNF-induced osteoclastogenesis.
Wei S; Kitaura H; Zhou P; Ross FP; Teitelbaum SL
J Clin Invest; 2005 Feb; 115(2):282-90. PubMed ID: 15668736
[TBL] [Abstract][Full Text] [Related]
36. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis.
Kobayashi N; Kadono Y; Naito A; Matsumoto K; Yamamoto T; Tanaka S; Inoue J
EMBO J; 2001 Mar; 20(6):1271-80. PubMed ID: 11250893
[TBL] [Abstract][Full Text] [Related]
37. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
38. Upstream stimulatory factors regulate OSCAR gene expression in RANKL-mediated osteoclast differentiation.
Kim JH; Kim K; Jin HM; Youn BU; Song I; Choi HS; Kim N
J Mol Biol; 2008 Nov; 383(3):502-11. PubMed ID: 18762192
[TBL] [Abstract][Full Text] [Related]
39. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation.
Lee NK; Choi YG; Baik JY; Han SY; Jeong DW; Bae YS; Kim N; Lee SY
Blood; 2005 Aug; 106(3):852-9. PubMed ID: 15817678
[TBL] [Abstract][Full Text] [Related]
40. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.
Sorrentino A; Thakur N; Grimsby S; Marcusson A; von Bulow V; Schuster N; Zhang S; Heldin CH; Landström M
Nat Cell Biol; 2008 Oct; 10(10):1199-207. PubMed ID: 18758450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
